Hims & Hers Health (HIMS) CLO Soleil Sells $101K of Stock

On October 14, 2026, Boughton Soleil, the Chief Legal Officer of Hims & Hers Health, Inc. (NYSE: HIMS), sold 3,461 shares for approximately $100,576. The sale price was $29.06 per share, and this transaction was planned in advance.

Inside Boughton Soleil's Trade

Soleil's sale comes as the stock trades below its 50-day moving average of $29.40. The recent trading price was around $28.08 as of October 16, 2026. This price is about 4.5% lower than the 50-day average.

Other Institutional Activity in Hims & Hers Health

Several institutional investors have been active in Hims & Hers Health recently. Blackrock Inc. increased its holdings by 2,365,182 shares, bringing its total to 28,703,514 shares valued at about $805.7 million. Vanguard Portfolio Management LLC added 375,773 shares for a total of 10,559,314 shares worth around $296.4 million. State Street Corporation also boosted its stake by 685,585 shares, resulting in a total of 8,145,699 shares valued at approximately $228.6 million. Meanwhile, Morgan Stanley reduced its holdings by 1,737,010 shares, now holding 7,152,498 shares worth about $200.8 million.

Hims & Hers Health, Inc. Stock Up 1.3%

As of October 16, 2026, Hims & Hers Health trades at $28.08, which is significantly below its 52-week high of $57.45. The stock is also below its target mean price of $31.15. Currently, it is trading about 51.1% lower than its 52-week high and 104.4% above its 52-week low of $13.74.

Recent Earnings

Hims & Hers Health reported trailing twelve-month revenue of approximately $2.58 billion, with a year-over-year revenue growth of 38.2%. However, the company has a negative net margin of -5.5% and a return on equity of -32.0%. The next earnings report is expected on November 9, 2026.

Insider Buying and Selling at Hims & Hers Health, Inc.

Before this trade, several insiders had also been active. On June 15, 2026, Chief Policy Officer Deborah Autor sold 15,396 shares at an average price of $30.17, totaling about $464,497.

Analysts Set New Price Targets

On August 11, 2026, Citigroup maintained a Neutral rating on Hims & Hers with a price target of $33.00, while Deutsche Bank maintained a Hold rating with a target of $26.00. Barclays also maintained an Overweight rating with a target of $35.00. The consensus among analysts is to hold the stock, with a mean price target of $31.15 across 13 opinions.

About Hims & Hers Health

Hims & Hers Health, Inc. is a healthcare company that connects consumers with licensed healthcare professionals. It offers a variety of prescription and non-prescription health products and services through its websites and mobile application. The company operates in several countries, including the United States and the United Kingdom.

Bottom Line

Investors should watch for the upcoming earnings report on November 9, 2026, to see how the company continues to perform. Soleil's planned sale reflects ongoing activity among insiders, which could provide insights into the company's outlook.